Compare DSS & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSS | APRE |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 8.4M |
| IPO Year | 2020 | 2019 |
| Metric | DSS | APRE |
|---|---|---|
| Price | $0.96 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 14.3K | ★ 354.3K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.45 | 21.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,085,000.00 | N/A |
| Revenue This Year | $1.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.55 |
| 52 Week High | $1.90 | $2.22 |
| Indicator | DSS | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 69.22 |
| Support Level | $0.83 | $0.57 |
| Resistance Level | $0.98 | $1.29 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 58.10 | 89.42 |
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.